Schizophrenia News and Research

Latest Schizophrenia News and Research

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

Climate change can cause major impact on global mental health

Leading mental health researchers are warning that some of the most important health consequences of climate change will be on mental health, yet this issue is unlikely to be given much attention at the UN climate change conference in Copenhagen next week.

4 Dec 2009

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

4 Dec 2009

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.

3 Dec 2009

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

2 Dec 2009

Integrated eating disorders center to be launched shortly

NewYork-Presbyterian Hospital, Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, in affiliation with the New York State Psychiatric Institute, announced the creation of an integrated eating disorders center. Opening today is a key clinical component of this new center -- The Outlook at NewYork-Presbyterian Hospital/Westchester Division in White Plains.

2 Dec 2009

Galenea and Otsuka Pharmaceutical extend their research and development collaboration

Galenea Corp. and Otsuka Pharmaceutical Co., Ltd. announced today the further extension of their research and development collaboration through 2011. This latest extension increases the collaboration term to seven years and brings the total committed funding to approximately $90 million.

2 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009

Antipsychotic medications increase the levels of inflammation markers, find researchers

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia.

2 Dec 2009

Pharmacy-based intervention improves antipsychotic adherence among patients with mental illnesses

Health systems should consider pharmacy-based interventions when involving patients who have poor follow-through taking medication.

24 Nov 2009

Groundbreaking discovery provides fundamental insights into neurological disorders

Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical School and neurologist at the Massachusetts General Hospital in Boston, on Thursday, November 19, presented his laboratory's research on the new field of study called "Connectivity" at the launch of the MINDlink Foundation.

21 Nov 2009

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.

21 Nov 2009

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

20 Nov 2009

Brain uses a mechanism to filter out distracting thoughts to focus on single information

The human brain is bombarded with all kinds of information, from the memory of last night's delicious dinner to the instructions from your boss at your morning meeting. But how do you "tune in" to just one thought or idea and ignore all the rest of what is going on around you, until it comes time to think of something else?

19 Nov 2009

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.

18 Nov 2009

Review of the results of Phase 2b clinical trial on PASCAL announced

ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.

18 Nov 2009

Schizophrenia News and Research

Latest Schizophrenia News and Research

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

FDA approves once-daily SEROQUEL XR Extended Release Tablets

Climate change can cause major impact on global mental health

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Psynova Neurotech, Roche collaborate in development of diagnostic immunoassays for schizophrenia treatment

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Integrated eating disorders center to be launched shortly

Galenea and Otsuka Pharmaceutical extend their research and development collaboration

MRI pioneer honored with MRC Millennium Medal

Antipsychotic medications increase the levels of inflammation markers, find researchers

Pharmacy-based intervention improves antipsychotic adherence among patients with mental illnesses

Groundbreaking discovery provides fundamental insights into neurological disorders

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

FDA approves sNDA for pediatric autism drug ABILIFY

Brain uses a mechanism to filter out distracting thoughts to focus on single information

BIMR wins a GO grant from the National Institute of Mental Health

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Review of the results of Phase 2b clinical trial on PASCAL announced

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Schizophrenia News and Research

Latest Schizophrenia News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in